China’s Zhejiang Hisun Pharmaceutical has gotten in progressively hotter water with the FDA, but its troubles have not kept it from striking deals globally…

Japan’s Fujifilm jumped into biologics contract manufacturing about 5 years ago by buying two plants from Merck & Co., when the U.S. drugmaker dropped that…

Despite a stumbling economy in recent years, Russia still holds a lot of appeal as an emerging market for drugmakers. Japan's Eisai is planning a major…

By year-end, the United Arab Emirates (UAE) can expect to have a new manufacturing plant producing drugs for the country as a Saudi drugmaker completes the…

Novartis put a Sandoz intermediates plant in Germany on the chopping block last year, saying that Asian competition had eviscerated the market for its products…

Recipharm has been continent-hopping to do a series of deals that expand both its geographic reach and its capabilities. Last fall, it struck a deal to buy an…

GlaxoSmithKline is upping its presence in India again, this week saying it'll spend INR500 million ($73 million) on a plant upgrade in Nashik to expand…

Regulators in Spain are punishing a Barcelona-based drugmaker for a series of manufacturing shortfalls, recalling all batches produced by the company, Farma…

Partnering